A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | NYU Langone Health

Go Back to All Clinical Trials

A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-small Cell Lung Cancer (nsclc)
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Eastern Cooperative Oncology Group (ECOG) PS of greater than and equal to 1 at screening and confirmed prior to randomization. 2) Participants must have a life expectancy of at least 3 months at the time of first dose. 3) Histologically confirmed metastatic NSCLC of SQ or NSQ histology with Stage IV A/B.

You may not be eligible for this study if the following are true:

1) Women who are breastfeeding b) Mutation status: i) EGFR mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations). 2) Participants with NSQ histology and unknown EGFR status. 3) Participants with leptomeningeal metastases (carcinomatous meningitis).